A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Novartis ( Novartis Vaccines )

ClinicalTrials.gov Identifier:

NCT00657683

First received: March 27, 2008

Last updated: December 7, 2011

Last verified: December 2011

History of Changes

Purpose

The goals of the proposed study are to evaluate the safety, tolerability and immunogenicity of a GBS vaccine. Previous studies suggest that immune responses against GBS can protect humans from infection.

Condition	Intervention	Phase
Invasive Group B Streptococcus (GBS) Disease	Biological: Monovalent GBS-CRM glycoconjugate vaccine Biological: Placebo	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention
Official Title:	A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age

Further study details as provided by Novartis:

Primary Outcome Measures:

To evaluate the safety and tolerability of an intramuscular GBS conjugate vaccine. Safety will be assessed by measuring the incidence of local and systemic reactogenicity, adverse events and serious adverse events. [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

To study the magnitude and durability of GBS-specific antibody responses over 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]


Enrollment:	65
Study Start Date:	December 2007
Study Completion Date:	May 2009
Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Biological: Monovalent GBS-CRM glycoconjugate vaccine 1 dose of GBS conjugate vaccine
Placebo Comparator: 2	Biological: Placebo 1 dose of placebo

Eligibility


Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy females 18 through 40 years of age;
have provided written informed consent after the nature of the study has been explained;
are available for all visits scheduled for the study (i.e. are not planning to leave the area before the end of the study period);
are in good health as determined by: medical history, physical assessment, clinical judgment of the investigator

Exclusion Criteria:

unwilling or unable to give written informed consent to participate in the study;
pregnant (serum pregnancy test)
unwilling to use acceptable birth control from screening and until at least 3 months after the final immunization
nursing (breastfeeding) mothers

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00657683

Locations


Switzerland
Institute for Pharmacokinetic and Analytical Studies, I.P.A.S. S.A.
Ligornetto, Switzerland, 6853

Sponsors and Collaborators

Novartis Vaccines

Investigators


Study Chair:	Novartis Vaccines	Novartis Vaccines

More Information

No publications provided


Responsible Party:	Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:	NCT00657683 History of Changes
Other Study ID Numbers:	V98P1
Study First Received:	March 27, 2008
Last Updated:	December 7, 2011
Health Authority:	Switzerland: Swissmedic

Keywords provided by Novartis:


GBS GBS prevention

ClinicalTrials.gov processed this record on February 27, 2015

To Top